USPSTF Recommends Depression Screening for Teens

Share this content:
USPSTF Recommends Depression Screening for Teens
USPSTF Recommends Depression Screening for Teens

TUESDAY, Sept. 8, 2015 (HealthDay News) -- The U.S. Preventive Services Task Force (USPSTF) recommends screening for major depressive disorder (MDD) in adolescents, but evidence is inadequate to assess screening tools for younger children. These findings form the basis of a draft recommendation statement published online Sept. 7 by the USPSTF.

Noting that children and adolescents with MDD typically have functional impairments in their performance at school or work, and in their interaction with their families and peers, researchers from the USPSTF reviewed the role of screening for MDD in children and adolescents.

The researchers found that there was adequate evidence that depression screening instruments could accurately identify MDD in primary care settings for adolescents aged 12 to 18 years, and recommended screening when adequate systems were in place for diagnosis, treatment, and monitoring (Grade B recommendation). In children aged 11 years and younger there were no studies of screening instruments for depression in primary care settings, and consequently the evidence was inadequate to weigh the benefits and harms of screening (Grade I recommendation). These findings form the basis of a draft recommendation statement which is available for comment from Sept. 8 to Oct. 5, 2015.

"Major depressive disorder can be a debilitating condition for adolescents and their families," USPSTF member Alex Kemper, M.D., M.P.H., said in a statement. "Screening in a primary care setting can help to identify youth with depression who might not otherwise be identified."

Evidence Review
Draft Recommendation Statement
Comment on Recommendation

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

WHO: Vaccine Hesitancy a Major Global Health Threat

WHO: Vaccine Hesitancy a Major Global Health Threat

Percentage of U.S. children 19 to 35 months who have not been vaccinated has quadrupled since 2001

FDA Down to 5 Weeks of Funding to Review New Drug Applications

FDA Down to 5 Weeks of Funding to ...

Agency cannot accept new fees or applications until the shutdown is over

FDA Approves First Generic Version of Epilepsy Drug Sabril

FDA Approves First Generic Version of Epilepsy Drug ...

Generic equivalents held to same vigorous manufacturing standards as brand-name drugs

is free, fast, and customized just for you!




Already a member?

Sign In Now »